Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Purpose
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Condition
- Pediatric Migraine
Eligibility
- Eligible Ages
- Between 6 Years and 17 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- History of migraine (with or without aura) for > 6 months before Screening according to the IHS Classification ICHD-319 specifications for pediatric migraine. History may be verified using both medical records and recall by the participant and/or participant's parent(s)/legal representative(s). 2. History of 1 to 8 moderate or severe attacks per month during the 2 months prior to enrollment, with attacks lasting > 3 hours without treatment, and attacks occurring at intervals > 24 hours. 3. Prophylactic migraine medication are permitted if the dose has been stable for at least 12 weeks prior to the Baseline Visit, and the dose is not expected to change during the course of the study. 1. Participants may remain on one (1) medication with possible migraine prophylactic effects, excluding CGRP antagonists [biologic or small molecule], during the treatment phases. 2. Concomitant use of a CGRP antagonist, such as erenumab or fremanezumab, is prohibited. 3. Previously discontinued prophylactic migraine medication must have done so at least 90 days prior to the Screening Visit. 4. Verbally distinguish between migraine and other types of headaches. 5. Participants must have a weight > 40 kg at the Screening Visit. 6. Adequate venous access for blood sampling. 7. Male and female participants ≥ 6 to < 18 years of age (participants must not reach their 18th birthday during the study).
Exclusion Criteria
- History of cluster headache or hemiplegic migraine headache. 2. Confounding and clinically significant pain syndrome that may interfere with the participant's ability to participate in this study. 3. Current psychiatric condition that is uncontrolled and/or untreated for a minimum of 6 months prior to the Screening Visit. Participants with a lifetime history of psychosis and/or mania. 4. History of suicidal behavior or major psychiatric disorder. 5. Current diagnosis or history of substance abuse; positive drug test at Screening. 6. History of moderate or severe head trauma or other neurological disorder (including seizure disorder) or systemic medical disease that is likely to affect central nervous system functioning. 7. Recent or planned surgery, requiring general anesthesia, <8 weeks prior to the Screening Visit. 8. Participant has had gastrointestinal surgery that interferes with physiological absorption and motility (i.e., gastric bypass, duodenectomy, or gastric banding). 9. Current diagnosis of viral hepatitis or a history of liver disease. 10. Conditions considered clinically relevant in the context of the study such as uncontrolled hypertension (high blood pressure), diabetes, a life-threatening allergy
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Sequential Assignment
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator BHV3000 (active drug) |
BHV3000 (rimegepant) 75 mg or 50 mg ODT |
|
|
Placebo Comparator Placebo |
Matching 75 mg or 50 mg ODT placebo |
|
Recruiting Locations
Scottsdale, Arizona 85253
Anaheim, California 92805
Costa Mesa, California 92627
Culver City, California 90230
Fountain Valley, California 92708
Fresno, California 93710
La Jolla, California 92093
Long Beach, California 90806
Long Beach, California 90806
Pomona, California 91767
San Bernardino, California 92408
Walnut Creek, California 94596
Aurora, Colorado 80045
Aurora, Colorado 80045
Cromwell, Connecticut 06416
Stamford, Connecticut 06905
Washington D.C., District of Columbia 20010
Miami, Florida 33166
Naples, Florida 34105
Orlando, Florida 32819
Atlanta, Georgia 30329
Atlanta, Georgia 30329
Brunswick, Georgia 31520
Decatur, Georgia 30030
Chicago, Illinois 60657
Naperville, Illinois 60563
Westfield, Indiana 46074
Sioux City, Iowa 51106
West Des Moines, Iowa 50265
Kansas City, Kansas 66214
Ann Arbor, Michigan 48104
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Royal Oak, Michigan 48073
Rochester, Minnesota 55905
Rochester, Minnesota 55905
Rochester, Minnesota 55905
Flowood, Mississippi 39232
Great Falls, Montana 59405
Missoula, Montana 59804
Missoula, Montana 59804
Missoula, Montana 59804
Omaha, Nebraska 68114
Neptune City, New Jersey 07753
Neptune City, New Jersey 07753
Amherst, New York 14226
Commack, New York 11725
Lake Success, New York 11042
New York, New York 10003
New York, New York 10021
Charlotte, North Carolina 28277
Durham, North Carolina 27701
Greensboro, North Carolina 27405
Akron, Ohio 44308
Cincinnati, Ohio 45229
Cincinnati, Ohio 45242
Cleveland, Ohio 44106
Portland, Oregon 97225
Portland, Oregon 97225
Portland, Oregon 97225
Philadelphia, Pennsylvania 19103
East Greenwich, Rhode Island 02818
Memphis, Tennessee 38103
Memphis, Tennessee 38103
Memphis, Tennessee 38103
Memphis, Tennessee 38105
Austin, Texas 78723
Austin, Texas 78749
Austin, Texas 78757
Bellaire, Texas 77401
Dallas, Texas 75235
Dallas, Texas 75235
Dallas, Texas 75251
Dallas, Texas 75390
El Paso, Texas 79912
Houston, Texas 77030
Houston, Texas 77054
Houston, Texas 77077
Houston, Texas 77094
Plano, Texas 75093
Salt Lake City, Utah 84107
Salt Lake City, Utah 84107
Charlottesville, Virginia 22902
Charlottesville, Virginia 22902
Charlottesville, Virginia 22902
Norfolk, Virginia 23507
Norfolk, Virginia 23507
Norfolk, Virginia 23510
Bellevue, Washington 98007
Seattle, Washington 98105
Seattle, Washington 98105
Kenosha, Wisconsin 53144
Madison, Wisconsin 53792
More Details
- NCT ID
- NCT04649242
- Status
- Recruiting
- Sponsor
- Pfizer
Study Contact
Pfizer Pfizer CT.gov Call Center1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com